Bicycle Therapeutics Shows Promise in 'Undruggable' EphA2 Target
Event summary
- Bicycle Therapeutics presented Phase 1/2 data at the AACR Annual Meeting 2026 showing a 40% ORR in EphA2+ mUC patients treated with nuzefatide pevedotin and nivolumab.
- The company has identified 8mg/m2 Q2W as the preferred dose for monotherapy of nuzefatide in pancreatic cancer.
- Human imaging data using a Bicycle Imaging Agent (BIA) targeting EphA2 demonstrated rapid tumor uptake and excretion in PDAC patients.
- Patient enrollment began in March 2026 for a Phase 2 clinical trial evaluating nuzefatide in recurrent PDAC, with the first patient dosed in April 2026.
The big picture
Bicycle Therapeutics' progress in targeting EphA2, a historically 'undruggable' target, represents a significant advancement in oncology drug development. The company's differentiated approach, leveraging its Bicycle® technology, offers a potential alternative to antibody-based therapies that have faced toxicity or efficacy challenges. Success in pancreatic cancer, a disease with limited treatment options, could unlock substantial commercial value and validate the platform for broader application.
What we're watching
- Clinical Efficacy
- The success of the Phase 2 trial in pancreatic cancer will be critical in validating nuzefatide's potential and driving further development.
- Regulatory Pathway
- Given the historical difficulty in targeting EphA2, regulatory acceptance of Bicycle's approach will hinge on demonstrating a favorable benefit-risk profile.
- Competitive Landscape
- The emergence of Bicycle's differentiated approach could attract increased competition in the EphA2-targeted therapy space, potentially impacting market share and pricing.
Related topics